| Description |
Windhover's must-attend event examines and explains the most important strategic alliances of the last two years, and looks ahead to what the industry can expect during 2006.
Here is your chance to network with peers who face similar challenges, and to benchmark your dealmaking against the best and the brightest. Maximize your strategic alliance opportunities by hearing leaders who share lessons learned, practical advice and strategies on how to build your R & D pipeline--both internally and externally.
Pharmaceutical Strategic Outlook Highlights:
-Network with top CEOs and senior bus dev execs from pharma, drug delivery, biotech, and specialty pharma, seeking investment and/or strategic partners
-Walk away with practical, real life lessons from some of the most experienced dealmakers in the industry
-Hear fresh perspectives on:
Big pharma outlicensing-why it's happening, what the caveats are
Novel deal structures-do they make sense?
When big pharma R&D creates biotech start-ups
The evolution of deal structures in specialty pharma
How spec pharma can build a pipeline and keep investors happy
The newest start-up models
The most interesting deal structures in large molecules, drug delivery and acquisitions
External influences: How MMA is affecting dealmaking
|
|
